share_log

Anika Therapeutics Analyst Ratings

Benzinga Analyst Ratings ·  Nov 9, 2022 22:31
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/09/2022 13.26% Barrington Research → $31 Upgrades Market Perform → Outperform
10/14/2022 -5.01% Stephens & Co. → $26 Reinstates → Equal-Weight
03/09/2022 Stephens & Co. Downgrades Overweight → Equal-Weight
11/16/2021 100.95% Stephens & Co. → $55 Initiates Coverage On → Overweight
07/16/2021 68.07% UBS → $46 Initiates Coverage On → Neutral
12/16/2020 57.11% Barrington Research → $43 Upgrades Market Perform → Outperform
01/21/2020 122.87% Sidoti & Co. → $61 Upgrades Neutral → Buy
11/05/2019 5.96% BWS Financial → $29 Initiates Coverage On → Sell
09/23/2019 First Analysis Downgrades Strong Buy → Outperform
02/22/2019 49.8% Sidoti & Co. $56 → $41 Downgrades Buy → Neutral
07/27/2018 Barrington Research Upgrades Market Perform → Outperform
06/20/2018 24.22% First Analysis $45 → $34 Downgrades Overweight → Equal-Weight
05/04/2018 Barrington Research Upgrades Market Perform → Outperform
02/23/2018 Barrington Research Downgrades Outperform → Market Perform
01/24/2018 First Analysis Upgrades Equal-Weight → Overweight

Anika Therapeutics Questions & Answers

What is the target price for Anika Therapeutics (ANIK)?

The latest price target for Anika Therapeutics (NASDAQ: ANIK) was reported by Barrington Research on November 9, 2022. The analyst firm set a price target for $31.00 expecting ANIK to rise to within 12 months (a possible 13.26% upside). 4 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Anika Therapeutics (ANIK)?

The latest analyst rating for Anika Therapeutics (NASDAQ: ANIK) was provided by Barrington Research, and Anika Therapeutics upgraded their outperform rating.

When is the next analyst rating going to be posted or updated for Anika Therapeutics (ANIK)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anika Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anika Therapeutics was filed on November 9, 2022 so you should expect the next rating to be made available sometime around November 9, 2023.

Is the Analyst Rating Anika Therapeutics (ANIK) correct?

While ratings are subjective and will change, the latest Anika Therapeutics (ANIK) rating was a upgraded with a price target of $0.00 to $31.00. The current price Anika Therapeutics (ANIK) is trading at is $27.37, which is within the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment